Formulation-based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives,Bioengineering & Translational Medicine

当前位置： X-MOL 学术 › Bioeng. Transl. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Formulation-based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives
Bioengineering & Translational Medicine ( IF 6.1 ) Pub Date : 2021-03-01 , DOI: 10.1002/btm2.10215
Marwa A Sallam _{1,

2} , Supriya Prakash ₁ , Ninad Kumbhojkar ₁ , Charles Wyatt Shields ₃ , Samir Mitragotri ₁

Affiliation

A growing variety of biological macromolecules are in development for use as active ingredients in topical therapies and vaccines. Dermal delivery of biomacromolecules offers several advantages compared to other delivery methods, including improved targetability, reduced systemic toxicity, and decreased degradation of drugs. However, this route of delivery is hampered by the barrier function of the skin. Recently, a large body of research has been directed toward improving the delivery of macromolecules to the skin, ranging from nucleic acids (NAs) to antigens, using noninvasive means. In this review, we discuss the latest formulation-based efforts to deliver antigens and NAs for vaccination and treatment of skin diseases. We provide a perspective of their advantages, limitations, and potential for clinical translation. The delivery platforms discussed in this review may provide formulation scientists and clinicians with a better vision of the alternatives for dermal delivery of biomacromolecules, which may facilitate the development of new patient-friendly prophylactic and therapeutic medicines.

中文翻译：

基于制剂的疫苗和治疗性核酸的真皮递送方法：最新进展和未来前景

越来越多的生物大分子正在开发中，用作局部治疗和疫苗的活性成分。与其他递送方法相比，生物大分子的皮肤递送具有多种优势，包括提高靶向性、降低全身毒性和减少药物降解。然而，这种递送途径受到皮肤屏障功能的阻碍。最近，大量研究致力于使用非侵入性手段改善从核酸 (NA) 到抗原等大分子向皮肤的输送。在这篇综述中，我们讨论了最新的基于配方的努力，以提供抗原和 NA 用于疫苗接种和治疗皮肤病。我们提供了它们的优势、局限性和临床转化潜力的观点。本综述中讨论的递送平台可以为制剂科学家和临床医生提供对生物大分子经皮递送替代方案的更好的认识，这可能有助于开发新的患者友好的预防和治疗药物。

更新日期：2021-03-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文